Understanding how melanoma spreads to the liver and resists immunotherapy

Mechanisms of liver metastasis and associated resistance to immunotherapy

NIH-funded research Columbia University Health Sciences · NIH-11043235

This study is looking at how melanoma spreads to the liver and why some treatments don’t work as well in those cases, using a special mouse model to find out more about the genes involved, which could help improve treatment options for patients with liver metastases.

Quick facts

Grant typeR37 grant
Study typeNIH-funded research
Funding institutionColumbia University Health Sciences NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-11043235 on NIH RePORTER

What this research studies

This research investigates the mechanisms behind melanoma's spread to the liver and how this affects the effectiveness of immunotherapy treatments. By using a novel mouse model that mimics human liver metastasis, researchers aim to identify the genetic factors that contribute to this spread and the resistance to treatment. The study employs advanced techniques, including CRISPR-Cas9 screening, to explore these mechanisms in detail, which could lead to improved therapeutic strategies for patients with liver metastases.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with melanoma that has metastasized to the liver.

Not a fit: Patients with melanoma that has not spread to the liver or those with other types of cancer may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective treatments for melanoma patients whose cancer has spread to the liver.

How similar studies have performed: Other research has shown promising results in understanding cancer metastasis and treatment resistance, but this specific approach is novel.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions advanced diseaseanti-cancer immunotherapyanticancer immunotherapy
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.